CO6531419A2 - Composiciones de enzima pancréatica y métodos para tratar pancreatitis e insuficiencia pancréatica - Google Patents

Composiciones de enzima pancréatica y métodos para tratar pancreatitis e insuficiencia pancréatica

Info

Publication number
CO6531419A2
CO6531419A2 CO12050658A CO12050658A CO6531419A2 CO 6531419 A2 CO6531419 A2 CO 6531419A2 CO 12050658 A CO12050658 A CO 12050658A CO 12050658 A CO12050658 A CO 12050658A CO 6531419 A2 CO6531419 A2 CO 6531419A2
Authority
CO
Colombia
Prior art keywords
pancreatic
digestive enzyme
methods
pancreatic insufficiency
enzyme compositions
Prior art date
Application number
CO12050658A
Other languages
English (en)
Spanish (es)
Inventor
Gopi M Venkatesh
Stephen Perrett
Konstantino Efthymiopulos
Original Assignee
Aptalis Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43730817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6531419(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aptalis Pharmatech Inc filed Critical Aptalis Pharmatech Inc
Publication of CO6531419A2 publication Critical patent/CO6531419A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CO12050658A 2009-09-17 2012-03-26 Composiciones de enzima pancréatica y métodos para tratar pancreatitis e insuficiencia pancréatica CO6531419A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24346709P 2009-09-17 2009-09-17

Publications (1)

Publication Number Publication Date
CO6531419A2 true CO6531419A2 (es) 2012-09-28

Family

ID=43730817

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12050658A CO6531419A2 (es) 2009-09-17 2012-03-26 Composiciones de enzima pancréatica y métodos para tratar pancreatitis e insuficiencia pancréatica

Country Status (23)

Country Link
US (2) US8784884B2 (enExample)
EP (1) EP2477645B1 (enExample)
JP (1) JP5877399B2 (enExample)
KR (1) KR101771752B1 (enExample)
CN (2) CN102630164B (enExample)
AR (1) AR078291A1 (enExample)
AU (1) AU2010295494B2 (enExample)
BR (1) BR112012005837A8 (enExample)
CA (1) CA2774269C (enExample)
CL (1) CL2012000658A1 (enExample)
CO (1) CO6531419A2 (enExample)
ES (1) ES2690661T3 (enExample)
HK (1) HK1218886A1 (enExample)
IL (2) IL218656A (enExample)
MX (1) MX2012003214A (enExample)
MY (1) MY161843A (enExample)
NZ (1) NZ599143A (enExample)
RU (1) RU2570376C2 (enExample)
SA (1) SA110310695B1 (enExample)
TW (2) TW201639545A (enExample)
UY (1) UY32896A (enExample)
WO (1) WO2011035079A1 (enExample)
ZA (1) ZA201202761B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
EP2079445B1 (en) 2007-02-20 2015-11-04 Aptalis Pharma Limited Stable digestive enzyme compositions
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
EP2621476B8 (en) * 2010-10-01 2020-12-23 Société des Produits Nestlé S.A. Enteric coated, low-strength pancrelipase formulations
RU2602183C2 (ru) * 2011-08-08 2016-11-10 Апталис Фарма Лтд. Способ проведения теста на растворение твердых композиций, содержащих пищеварительные ферменты
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
WO2015020943A2 (en) 2013-08-09 2015-02-12 Aptalis Pharma Ltd. Digestive enzyme composition suitable for enteral administration
FR3079146B1 (fr) * 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
WO2021202363A1 (en) * 2020-03-30 2021-10-07 Wall Jai Combined animal-derived and synthetically produced pancreatic enzyme replacement therapy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4447412A (en) 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5460812A (en) 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
DE69728857T3 (de) 1996-02-09 2010-02-18 Quadrant Drug Delivery Ltd., Ruddington Feste arzneimittel enthaltend trehalose
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
CN1156308C (zh) * 2002-04-19 2004-07-07 北京世诺医药科技有限公司 多酶组合胶囊
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
EP1596838A2 (en) 2003-02-11 2005-11-23 Torrent Pharmaceuticals Ltd Once a day orally administered pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
AU2004285558A1 (en) * 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (CCK) concentration and for treating pain
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
DE602005009677D1 (de) 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
DK1755656T3 (da) * 2004-05-24 2010-10-04 Novozymes As Enzymer til farmaceutisk anvendelse
HUE031245T2 (en) 2004-10-14 2017-06-28 Lilly Co Eli Preparations containing lipase, protease and amylase for the treatment of pancreatic insufficiency
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CA2612648A1 (en) * 2005-06-24 2006-12-28 Novozymes A/S Lipases for pharmaceutical use
US20070025977A1 (en) 2005-07-21 2007-02-01 Mulberg Andrew E Method of treating steatorrhea in infants
MX2008000850A (es) 2005-07-29 2008-03-18 Solvay Pharm Gmbh Procedimientos para la fabricacion de polvo de pancreatina esterilizada.
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US8071089B2 (en) 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
MY147954A (en) * 2006-05-26 2013-02-15 Nestec Sa Methods of use and nutritional compositions of touchi extract
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
US20090117180A1 (en) 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
EP2079445B1 (en) 2007-02-20 2015-11-04 Aptalis Pharma Limited Stable digestive enzyme compositions
US20110171294A1 (en) 2008-09-30 2011-07-14 Dsm Ip Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency

Also Published As

Publication number Publication date
CN102630164A (zh) 2012-08-08
EP2477645B1 (en) 2018-08-15
TWI572372B (zh) 2017-03-01
IL245875A0 (en) 2016-07-31
US8784884B2 (en) 2014-07-22
CA2774269C (en) 2017-03-21
KR101771752B1 (ko) 2017-08-25
RU2570376C2 (ru) 2015-12-10
MY161843A (en) 2017-05-15
MX2012003214A (es) 2012-08-01
BR112012005837A2 (pt) 2017-05-30
SA110310695B1 (ar) 2014-11-26
US20140287035A1 (en) 2014-09-25
HK1218886A1 (zh) 2017-03-17
NZ599143A (en) 2014-05-30
AU2010295494A1 (en) 2012-03-29
IL218656A (en) 2017-12-31
EP2477645A1 (en) 2012-07-25
RU2012113253A (ru) 2013-10-27
IL218656A0 (en) 2012-05-31
CA2774269A1 (en) 2011-03-24
US20110064799A1 (en) 2011-03-17
JP5877399B2 (ja) 2016-03-08
UY32896A (es) 2011-02-28
CN102630164B (zh) 2015-09-16
WO2011035079A1 (en) 2011-03-24
JP2013505255A (ja) 2013-02-14
ZA201202761B (en) 2012-12-27
AR078291A1 (es) 2011-10-26
TW201113052A (en) 2011-04-16
ES2690661T3 (es) 2018-11-21
EP2477645A4 (en) 2014-06-25
KR20120100915A (ko) 2012-09-12
AU2010295494B2 (en) 2014-09-25
CL2012000658A1 (es) 2012-09-28
CN105214073A (zh) 2016-01-06
US20160051472A9 (en) 2016-02-25
TW201639545A (zh) 2016-11-16
BR112012005837A8 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
CO6531419A2 (es) Composiciones de enzima pancréatica y métodos para tratar pancreatitis e insuficiencia pancréatica
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
CO6700848A2 (es) Formulaciones recubiertas entéricas de pancrelipilasa, de baja intensidad
BR112014014057A2 (pt) composições de cuidado oral branqueadoras
CR20120625A (es) Métodos de tratamiento contra el cáncer pancreático
PH12012502162A1 (en) Combination therapy
BR112013004768A2 (pt) dispositivos e métodos para dilatar uma abertura de seio parasanal e para o tratamento de sinusite
EP2349279A4 (en) MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
EA201991014A1 (ru) Лечение диабета
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
BR112013024968A2 (pt) composição farmacêutica, e, método de tratamento de uma convulsão
NZ626578A (en) Compositions and methods for treating metabolic disorders
WO2008144130A3 (en) Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties
AR075413A1 (es) Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112012027092A2 (pt) métodos e composiões para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal
EP2558102A4 (en) SYNERGISTIC INTERACTION OF AT LEAST ONE COMPONENT OF VITAMIN E AND TYROSINASE INHIBITORS FOR DERMATOLOGICAL APPLICATIONS
JP2013505255A5 (enExample)
EA201270192A1 (ru) Композиции и способы применения для пострадиационной защиты
CA3065816C (en) TREATMENT OF HEART DISEASE BY INHIBITION OF THE ACTION OF MUSCLE PROTEIN-ANCHORING PROTEINS KINASES A (MAKAP)
MX346316B (es) Formulacion farmaceutica o nutraceutica.
BR112012008951A2 (pt) tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
PL379512A1 (pl) Nowe metody i ich zastosowanie